The European Medicines Agency (EMA) is a decentralized body of the European Union headquartered in London. Its main mission is the protection and promotion of health through the evaluation and supervision of drugs for human and veterinary use. The EMA issues marketing authorizations and continuously monitors drug safety through a pharmacovigilance network.
Following Brexit, the agency is likely to leave its London headquarters. Also the Lille metropolis has already applied to host this institution. Among the various assets mentioned by the capital of Hauts-de-France: the existence of the GIE Eurasanté which brings together the Nutrition Health Longevity competitiveness cluster, a bio-incubator specializing in health and the Eurasanté park dedicated to hosting activities . But also the CHRU of Lille “important center promoting clinical studies for the pharmaceutical industry” and the Faculty of Pharmaceutical and Biological Sciences, “one of the most important in France”.
Finally, the fastest Eurostars connect London to Lille in 3 hours, which is not negligible for the current employees of the European agency whose families would remain in Great Britain.
Read also :
Medicines and heat: watch out for interactions
A book denounces the side effects of drugs
